Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing stabilised hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, has entered into a non-exclusive distribution agreement with Gabriel Science, LLC for the sale of Microcyn® Technology products into the dental market and has accepted its first order.
Endocyn®, a Microcyn® Technology product manufactured by Sonoma, is a biocompatible root canal irrigation material that does not stain teeth or restorations. In a study conducted by the Departments of Endodontics and Cell Biology and Anatomy at Louisiana State University School of Dentistry published in the Journal of Endodontics, Regenerative Endodontics, Endocyn demonstrated less cellular toxicity compared to traditional endodontic irrigation material such as sodium hypochlorite.
“We believe Endocyn and the Microcyn family of hypochlorous acid products are the next generation of materials to help in the management of a myriad of dental, head, and neck conditions,” said Dr Mark Fontenot, managing member at Gabriel Science, LLC. “The Microcyn family of HOCl products is a much-needed addition to the treatment options available to dental healthcare providers given Microcyn’s superior performance.”
“We are pleased to bring this cutting-edge advance in dental products to the United States (US) market and to partner with Gabriel Science,” said Amy Trombly, CEO of Sonoma Pharmaceuticals. “Our proprietary Microcyn technology is truly the next-generation formulation in terms of superior antimicrobial impact, shelf stability and safety. This partnership also furthers Sonoma’s strategy of expanding its offerings of Microcyn-powered products available in the US market.”
